Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 521-528

  Tsuchiya, Takanori ^a   Fukuda, Takashi ^b   Furuiye, Masashi ^a,c   Kawabuchi, Koichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Furuiye Clinic   (Japan)

Author keywords

Consolidation therapy; Cost effectiveness analysis; Erlotinib; Non small cell lung cancer; Pemetrexed; Pharmacoeconomics

Indexed keywords

CLOBETASONE BUTYRATE; ERLOTINIB; LOPERAMIDE; PEMETREXED; RAMOSETRON;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HIDDEN MARKOV MODEL; HISTOPATHOLOGY; HUMAN; JAPAN; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY; ECONOMICS, PHARMACEUTICAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 80755190102     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.002     Document Type: Article

References (30)

1. Cancer mortality (1958-2008) [Internet] 2008, Center for Cancer Control and Information Services, Tokyo, [cited 2010 June 1]. Available from: http://.jp/professional/statistics/statistics.html in [Japanese].
2. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
3. D'Addario G., Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20:iv68-iv70.
4. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
5. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253-263.
6. Gridelli C., Maione P., Rossi A., Ferrara M.L., Bareschino M.A., Schetino C., et al. Potential treatment opinions after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. Oncologist 2009, 14:137-147.
7. Jalal S.I., Ademuyiwa F.O., Hanna N.H. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Curr Opin Oncol 2009, 21:110-115.
8. Fedias P.M., Dakhil S.R., Lyss A.P., Loesh D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
9. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
10. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
11. Bach P.B. Limits on Medicare's ability to control rising spending on cancer drugs. New Engl J Med 2009, 360:626-633.
12. Fojo T.G.C. How much is life worth: Cetuximab, non-small cell lung cancer, and the 440 billion question. J Natl Cancer Inst 2009, 101:1044-1048.
13. Summary of medical care expenditure in 2007 [Internet] 2009, Ministry of Health, Labour and Welfare, Tokyo, [cited 2010 August 25]. Available from: http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/07/index.html [in Japanese].
14. Koinuma N. Economic burden of cancer patients undergoing oral chemotherapy. Jpn J Cancer Chemother 2010, 37:1230-1233. [in Japanese].
15. Asukai Y., Valladares A., Camps C., Wood E., Taipale K., Arellano J., et al. Cost-Effectiveness analysis of pemetrexed versus docetaxel in second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer [Internet] 2010, 10. [cited 2010 June 01]. Available from: http://www.biomedcentral.com/1471-2407/10/26.
16. Carlson J.J., Reyes C., Oestreicher N., Lubeck D., Ramsey S.D., Veenstra D.L. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008, 61:405-415.
17. Klein R., Muehlenbein C., Liepa A.M., Babineaux S., Wielage R., Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009, 4:1404-1414.
18. Klein R., Wielage R., Muehlenbein C., Liepa A.M., Babineaux S., Lawson A., et al. Cost-Effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010, 5:1263-1272.
19. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programs 2005, Oxford University Press, New York. 3rd ed.
20. Nafees B., Stafford M., Gavriel S., Bhalla S., Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes [Internet] 2008, 6. [cited 2010 Jul 14]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579282/pdf/1477-7525-6-84.pdf.
21. Shiroiwa T., Sung Y.K., Fukuda T., Lang H.C., Bae S.C., Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 2010, 19:422-437.
22. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previous treated non-small-cell lung cancer. New Engl J Med 2005, 353:123-132.
23. National Health and Nutrition Survey [Internet] 2010, Ministry of Health, Labour and Welfare, Tokyo, [cited 2010 July 14]. Available from: http://www.mhlw.go.jp/bunya/kenkou/eiyou09/01.html [in Japanese].
24. Purchasing power parties - comparative price level [Internet] 2010, Organization for Economic Co-Operation and Development (OECD), Paris, [cited 2010 July 23]. Available from: http://stats.oecd.org/Index.aspx?DataSetCode=PPPGDP.
25. Quick reference of medical service fee 2008, Igakutsushinsha, Tokyo, (2009 enlarged edition) [in Japanese].
26. National health insurance drug price standard 2008, Jiho, Tokyo, [in Japanese].
27. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York.
28. Meropol N.J., Schrag D., Smith T.J., Mulvey T.M., Langdon R.M., Blum D., et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009, 27:3868-3874.
29. National institute for health and clinical excellence appraising life-extending, end of life treatments [Internet] 2009, National Institute for Health and Clinical Excellence (NICE), London, [cited 2010 Dec 01]. Available from: http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf.
30. Mayor S. NICE recommends kidney cancer drug it previous rejected on cost grounds. Br Med J 2009, 338:b499.